The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 15, 2022
Filed:
Jan. 30, 2021
Janssen Pharmaceuticals, Inc., Titusville, NJ (US);
Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);
Johannes Petrus Maria Langedijk, Amsterdam, NL;
Lucy Rutten, Rijnsburg, NL;
Mark Johannes Gerardus Bakkers, Haarsteeg, NL;
Rinke Bos, Oegstgeest, NL;
Frank Wegmann, Leiden, NL;
David Adrianus Theodorus Maria Zuijdgeest, The Hague, NL;
Dan H. Barouch, Newton, MA (US);
An Vandebosch, Herentals, BE;
Mathieu Claude Michel Le Gars, Antwerp, BE;
Jerald C. Sadoff, Washington, DC (US);
Janssen Pharmaceuticals, Inc., Titusville, NJ (US);
Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);
Abstract
The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.